Terms: = Kidney tumors AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Diagnosis
28 results:
1. Downregulation of praja2 restrains endocytosis and boosts tyrosine kinase receptors in kidney cancer.
Rinaldi L; Chiuso F; Senatore E; Borzacchiello D; Lignitto L; Iannucci R; Donne RD; Fuggi M; Reale C; Russo F; Russo NA; Giurato G; Rizzo F; Sellitto A; Santangelo M; De Biase D; Paciello O; D'Ambrosio C; Amente S; Garbi C; Dalla E; Scaloni A; Weisz A; Ambrosino C; Insabato L; Feliciello A
Commun Biol; 2024 Feb; 7(1):208. PubMed ID: 38379085
[TBL] [Abstract] [Full Text] [Related]
2. kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract] [Full Text] [Related]
3. Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
Korkmaz M; Eryılmaz MK; Koçak MZ; Er MM; Hendem E; Demirkıran A; Araz M; Karaağaç M; Artaç M
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147975
[TBL] [Abstract] [Full Text] [Related]
4. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (vegfr-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract] [Full Text] [Related]
5. Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma As First-line Therapy: A Single Institution 13-year Experience.
Bekku K; Tsugawa T; Tsuboi K; Noda G; Inoue Y; Murao W; Ebara S
Acta Med Okayama; 2022 Aug; 76(4):465-472. PubMed ID: 36123162
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Thouvenin J; Alhalabi O; Carlo M; Carril-Ajuria L; Hirsch L; Martinez-Chanza N; Négrier S; Campedel L; Martini D; Borchiellini D; Chahoud J; Lodi M; Barthélémy P; Hasanov E; Hahn AW; Gil T; Viswanathan SR; Bakouny Z; Msaouel P; Asim Bilen M; Choueiri TK; Albiges L; Tannir NM; Malouf GG
Oncologist; 2022 Dec; 27(12):1041-1047. PubMed ID: 35979929
[TBL] [Abstract] [Full Text] [Related]
7. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK; Rumble RB; Van Veldhuizen PJ; Al-Ahmadie H; Emamekhoo H; Hauke RJ; Louie AV; Milowsky MI; Molina AM; Rose TL; Siva S; Zaorsky NG; Zhang T; Qamar R; Kungel TM; Lewis B; Singer EA
J Clin Oncol; 2022 Sep; 40(25):2957-2995. PubMed ID: 35728020
[TBL] [Abstract] [Full Text] [Related]
8. DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma.
Zhu Y; Liu X; Wang Y; Pan Y; Han X; Peng B; Zhang X; Niu S; Wang H; Ye Q; Gu Y; Gao S
Cell Death Dis; 2022 May; 13(5):456. PubMed ID: 35562342
[TBL] [Abstract] [Full Text] [Related]
9. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
10. Nivolumab, nivolumab-ipilimumab, and vegfr-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
[TBL] [Abstract] [Full Text] [Related]
11. Screening and identification of key biomarkers of papillary renal cell carcinoma by bioinformatic analysis.
Xu Y; Kong D; Li Z; Qian L; Li J; Zou C
PLoS One; 2021; 16(8):e0254868. PubMed ID: 34358255
[TBL] [Abstract] [Full Text] [Related]
12. Rare anti-vegfr therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient.
Catalano F; Rebuzzi SE; Murianni V; Damassi A; Martelli V; Borea R; Rollandi GA; Fornarini G
Anticancer Drugs; 2022 Jan; 33(1):e724-e729. PubMed ID: 34261919
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive Analysis of Regulatory Network for LINC00472 in Clear Cell Renal Cell Carcinoma.
Gao S; Wang Z
J Healthc Eng; 2021; 2021():3533608. PubMed ID: 34221297
[TBL] [Abstract] [Full Text] [Related]
14. [Side effects of immune checkpoint inhibitor treatment of urological tumors].
Grimm MO; Gottschlich T; Ali N; Foller S; Leucht K
Urologe A; 2021 Jun; 60(6):803-815. PubMed ID: 34100956
[TBL] [Abstract] [Full Text] [Related]
15. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
[TBL] [Abstract] [Full Text] [Related]
16. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract] [Full Text] [Related]
17. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
[TBL] [Abstract] [Full Text] [Related]
18. Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma.
Carretero-González A; Salamanca Santamaría J; Castellano D; de Velasco G
Medicine (Baltimore); 2019 Nov; 98(47):e18098. PubMed ID: 31764847
[TBL] [Abstract] [Full Text] [Related]
19. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line vegfr-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract] [Full Text] [Related]
20. Renal Cell Carcinoma With Extensive Tumor Thrombus Into the Inferior Vena Cava and Right Atrium in a 70-Year-Old Man.
Oltean MA; Matuz R; Sitar-Taut A; Mihailov A; Rednic N; Tantau A; Toganel R; Minciuna IA; Orasan O; Muresan F; Cozma A
Am J Mens Health; 2019; 13(3):1557988319846404. PubMed ID: 31046582
[TBL] [Abstract] [Full Text] [Related]
[Next]
